The Drugs Controller General of India has approved of the commercial launch of 'Feluda', the Tata CRISPR Covid-19 test
After recording more than 90,000 Covid-19 cases consecutively for five days, on Sunday, India witnessed around 87,000 new cases.
The Drugs Controller General of India has approved of the commercial launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Covid-19 test.
Tune in to the podcast for more
 "Covid updates: Guidelines for schools, India's first low-cost test & more")
